Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1974 1
1980 4
1981 1
1982 2
1987 2
1988 1
1989 2
2003 1
2004 2
2005 2
2006 1
2007 2
2008 2
2010 2
2011 2
2012 1
2013 1
2014 6
2015 5
2016 6
2017 4
2018 2
2019 1
2021 2
2022 2
2023 3
2024 7
2025 1
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of first-line immuno-oncology combinations with molecular targeted therapy in patients with advanced renal cell carcinoma undergoing hemodialysis: a real-world multicenter retrospective study.
Ueda K, Kurata H, Murakami Y, Minato A, Shiota M, Nakanishi S, Kiyoshima K, Inoue T, Kumagae H, Irie S, Noguchi M, Tatarano S, Matsuzaki H, Tokuda Y, Sawada A, Abe T, Oshiro Y, Harada S, Igawa T. Ueda K, et al. Among authors: kiyoshima k. Int J Clin Oncol. 2026 Jan;31(1):160-171. doi: 10.1007/s10147-025-02933-9. Epub 2025 Dec 2. Int J Clin Oncol. 2026. PMID: 41329256
Organ-Specific Tumor Response to Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study.
Minato A, Furubayashi N, Tomoda T, Masaoka H, Song Y, Hori Y, Kiyoshima K, Negishi T, Kuroiwa K, Seki N, Tomisaki I, Harada K, Nakamura M, Fujimoto N. Minato A, et al. Among authors: kiyoshima k. Clin Genitourin Cancer. 2024 Oct;22(5):102148. doi: 10.1016/j.clgc.2024.102148. Epub 2024 Jul 2. Clin Genitourin Cancer. 2024. PMID: 39033710 Free article.
Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study.
Minato A, Furubayashi N, Nagata Y, Tomoda T, Masaoka H, Song Y, Hori Y, Kiyoshima K, Negishi T, Kuroiwa K, Seki N, Tomisaki I, Harada K, Nakamura M, Fujimoto N. Minato A, et al. Among authors: kiyoshima k. Curr Oncol. 2024 Feb 3;31(2):862-871. doi: 10.3390/curroncol31020064. Curr Oncol. 2024. PMID: 38392058 Free PMC article.
Enfortumab Vedotin for Elderly Advanced Urothelial Carcinoma Patients or Those With a Poor Performance Status.
Furubayashi N, Minato A, Tomoda T, Masaoka H, Hori Y, Kiyoshima K, Negishi T, Haraguchi Y, Koga T, Song Y, Harada K, Kuroiwa K, Seki N, Fujimoto N, Nakamura M; Uro-Oncology Group in Kyushu (UROKYU). Furubayashi N, et al. Among authors: kiyoshima k. Anticancer Res. 2024 Aug;44(8):3409-3417. doi: 10.21873/anticanres.17161. Anticancer Res. 2024. PMID: 39060060
61 results